
    
      This is a double-blind, randomized, placebo-controlled, multicenter study of CFZ533 in 2
      distinct populations (cohorts) of patients with Sj√∂gren's Syndrome: 1) moderate-to-severe
      disease (systemic and symptomatic involvement) and; 2) low systemic involvement but high
      symptom burden.

      The study includes up to 6 weeks screning period, 48 weeks of treatment (divided into
      treatment periods of 24 weeks each) and 12 weeks follow up. Study treament will be
      administered as bi-weekly subcutaneous injections.
    
  